Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 88-92 , April 2006

The ROC analysis for different time points during oral glucose tolerance test

Received 30 May 2005 ,Accepted 13 September 2005.

References 

  1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28:s37–s42
  2. Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 2001;344:1343–1350
  3. The Diabetes Prevention Program Research Group: reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin, N. Engl. J. Med. 346 (2002) 393–403.
  4. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002;359:2072–2077
  5. American Diabetes Association, National Institutes of Diabetes Digestive Diseases and Kidney Diseases: the prevention or delay of type 2 diabetes, Diabetes Care 25 (2002) 742–749.
  6. World Health Organization Study Group on Diabetes Mellitus, Technical Report Series no. 727, World Health Organization, Geneva, 1985.
  7. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183–1197.
  8. Hanley JA, McNeil BJ. A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology. 1983;148:839–843
  9. Sox HC, Blatt MA, Higgins MC, et al. Medical Decision Making. Boston, MA: Butterworths; 1988;pp. 130–145
  10. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional therapy and risk of complications in patients with type 2 diabetes mellitus—UKPDS 33. Lancet. 1998;352:837–853
  11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes mellitus—UKPDS 38. Br. Med. J. 1998;317:703–712
  12. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against National Screening Committee criteria. Br. Med. J. 2001;322:986–988
  13. Chen M, Bergman RN, Pacini G, et al. Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased beta-cell function. J. Clin. Endocrinol. Metab. 1985;60:13–20
  14. Broughton DL, James OW, Alberti KG, et al. Peripheral and hepatic insulin sensitivity in healthy elderly human subjects. Eur. J. Clin. Invest. 1991;21:13–21
  15. Ferrannini E, Vichi S, Beck-Nielsen H, et al. Insulin action and age: European group for the study of insulin resistance (EGIR). Diabetes. 1996;45:947–953
  16. De Fronzo RA. Glucose intolerance and aging. Diabetes Care. 1981;4:493–501
  17. Rowe JW, Minaker KL, Pallotta JA, et al. Characterization of the insulin resistance of aging. J. Clin. Invest. 1983;71:1581–1587
  18. Elahi D, Muller DC, McAloon-Dyke M, et al. The effect of age on insulin response and glucose utilization during four hyperglycemic plateaus. Exp. Gerontol. 1993;28:393–409
  19. Pacini G, Valerio A, Beccaro F, et al. Insulin sensitivity and beta-cell responsivity are not decreased in elderly subjects with normal OGTT. J. Am. Geriatr. Soc. 1988;36:317–323
  20. Muller DC, Elahi D, Tobin JD, et al. The effect of age on insulin resistance and secretion: a review. Semin. Nephrol. 1996;16:289–298

PII: S0168-8227(05)00377-3

doi: 10.1016/j.diabres.2005.09.013

Diabetes Research and Clinical Practice
Volume 72, Issue 1 , Pages 88-92 , April 2006

Article Tools

* Image Usage & Resolution